Follow-on bonanza drives U.K. investment in life science stocks past £1B

Nick Paul Taylor

At first glance, 2015 looks like the year the London Stock Exchange turned its back on biotech once again. Acacia Pharma and Shield Therapeutics both tried and failed to be 2015's Circassia, the big success story of 2014, leaving AIM listings and outliers such as PureTech as the most notable London IPOs of the year. And yet, from another angle, 2015 looks like a landmark year.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS